![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0040.png)
36
Biophysics of Proteins at Surfaces: Assembly, Activation, Signaling
Thursday Speaker Abstracts
GM
1
Nanodomains Inhibit the Oligomerization of Membrane Bound ß-amyloid Monomers
Mariana Amaro
1
, Radek Sachl
1
, Gokcan Aydogan
1
, Ilya I. Mikhalyov
2
, Martin Hof
1
.
1
J. Heyrovský Institute of Physical Chemistry of the C.A.S. v.v.i., Prague, Prague 8, Czech
Republic,
2
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the R.A.S., Moscow,
Russian Federation.
Oligomers of ß-amyloid (Aß) are thought to spark neuronal dysfunction, cell death and
Alzheimer disease onset.
1
The monosialoganglioside GM
1
has been suggested to seed
aggregation of Aßand thus enhance the formation of Aß's cytotoxic oligomers.
2
However, such
studies are commonly performed in system with high concentrations of GM
1
, sphingomyelin,
cholesterol, and amyloid peptides, thus their pertinence to the physiological oligomerization of
Aß on cellular membranes might be low. In this work, we strive to emulate more physiological
conditions.
The oligomerization of Aß on lipid bilayers containing essential components of the neuronal
plasma membrane is addressed using the single molecule sensitivity of fluorescence. The
oligomerization of Aß is characterized by changes of its lateral diffusion coefficient and by
Cross-Correlation Fluorescence Correlation Spectroscopy.
3
A novel Fluorescence Lifetime
Förster Resonance Energy Transfer approach
4
is used to characterize heterogeneities on the
nanometer scale in lipid bilayers.
We find that sphingomyelin is a key trigger for the in-membrane oligomerization of Aß
monomers. Physiological levels of GM
1
, organized in nanodomains, do not seed Aß's
oligomerization. Moreover, GM
1
counteracts the effect of sphingomyelin and prevents the
oligomerization of Aß. This molecular evidence for GM
1
as an inhibitor of the oligomerization
of Aß supports the idea of GM
1
as a protective factor
5
, rather than GM
1
as an enhancer of the
toxic oligomerization of Aß.
1
K. A. Conway, et al. PNAS 97 (2000); M. Bucciantini, et al. Nature 416 (2002); G. M. Shankar,
et al. Nat. Med. 14 (2008)
2
K. Yanagisawa, J. Neurochem. 116 (2011)
3
A. Benda, et al. Langmuir 19 (2003); F. Heinemann, et al. Langmuir 28 (2012); R. Machan, M.
Hof, Biochim. Biophys. Acta 1798 (2010).
4
R. Sachl, et al. BBA-Mol. Cell Res. 1853 (2015)
5
F. Kreutz, et al. Neurochem Res. 38 (2013)